143 related articles for article (PubMed ID: 17226960)
1. Influence of different spacers on the biological profile of a DOTA-somatostatin analogue.
Antunes P; Ginj M; Walter MA; Chen J; Reubi JC; Maecke HR
Bioconjug Chem; 2007; 18(1):84-92. PubMed ID: 17226960
[TBL] [Abstract][Full Text] [Related]
2. DOTA-NOC, a high-affinity ligand of somatostatin receptor subtypes 2, 3 and 5 for labelling with various radiometals.
Wild D; Schmitt JS; Ginj M; Mäcke HR; Bernard BF; Krenning E; De Jong M; Wenger S; Reubi JC
Eur J Nucl Med Mol Imaging; 2003 Oct; 30(10):1338-47. PubMed ID: 12937948
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of [99mTc/EDDA/HYNIC0]octreotide derivatives compared with [111In-DOTA0,Tyr3, Thr8]octreotide and [111In-DTPA0]octreotide: does tumor or pancreas uptake correlate with the rate of internalization?
Storch D; Béhé M; Walter MA; Chen J; Powell P; Mikolajczak R; Mäcke HR
J Nucl Med; 2005 Sep; 46(9):1561-9. PubMed ID: 16157541
[TBL] [Abstract][Full Text] [Related]
4. Are radiogallium-labelled DOTA-conjugated somatostatin analogues superior to those labelled with other radiometals?
Antunes P; Ginj M; Zhang H; Waser B; Baum RP; Reubi JC; Maecke H
Eur J Nucl Med Mol Imaging; 2007 Jul; 34(7):982-93. PubMed ID: 17225119
[TBL] [Abstract][Full Text] [Related]
5. NODAGATOC, a new chelator-coupled somatostatin analogue labeled with [67/68Ga] and [111In] for SPECT, PET, and targeted therapeutic applications of somatostatin receptor (hsst2) expressing tumors.
Eisenwiener KP; Prata MI; Buschmann I; Zhang HW; Santos AC; Wenger S; Reubi JC; Mäcke HR
Bioconjug Chem; 2002; 13(3):530-41. PubMed ID: 12009943
[TBL] [Abstract][Full Text] [Related]
6. [111In-DOTA]Somatostatin-14 analogs as potential pansomatostatin-like radiotracers - first results of a preclinical study.
Tatsi A; Maina T; Cescato R; Waser B; Krenning EP; de Jong M; Cordopatis P; Reubi JC; Nock BA
EJNMMI Res; 2012 Jun; 2(1):25. PubMed ID: 22682002
[TBL] [Abstract][Full Text] [Related]
7. [DOTA]Somatostatin-14 analogs and their (111)In-radioligands: effects of decreasing ring-size on sst1-5 profile, stability and tumor targeting.
Tatsi A; Maina T; Cescato R; Waser B; Krenning EP; de Jong M; Cordopatis P; Reubi JC; Nock BA
Eur J Med Chem; 2014 Feb; 73():30-7. PubMed ID: 24378707
[TBL] [Abstract][Full Text] [Related]
8. Preclinical evaluation of new and highly potent analogues of octreotide for predictive imaging and targeted radiotherapy.
Ginj M; Chen J; Walter MA; Eltschinger V; Reubi JC; Maecke HR
Clin Cancer Res; 2005 Feb; 11(3):1136-45. PubMed ID: 15709181
[TBL] [Abstract][Full Text] [Related]
9. PEG spacers of different length influence the biological profile of bombesin-based radiolabeled antagonists.
Jamous M; Tamma ML; Gourni E; Waser B; Reubi JC; Maecke HR; Mansi R
Nucl Med Biol; 2014 Jul; 41(6):464-70. PubMed ID: 24780298
[TBL] [Abstract][Full Text] [Related]
10. Preclinical comparison in AR4-2J tumor-bearing mice of four radiolabeled 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid-somatostatin analogs for tumor diagnosis and internal radiotherapy.
Froidevaux S; Heppeler A; Eberle AN; Meier AM; Häusler M; Beglinger C; Béhé M; Powell P; Mäcke HR
Endocrinology; 2000 Sep; 141(9):3304-12. PubMed ID: 10965902
[TBL] [Abstract][Full Text] [Related]
11. Internalization of sst2, sst3, and sst5 receptors: effects of somatostatin agonists and antagonists.
Cescato R; Schulz S; Waser B; Eltschinger V; Rivier JE; Wester HJ; Culler M; Ginj M; Liu Q; Schonbrunn A; Reubi JC
J Nucl Med; 2006 Mar; 47(3):502-11. PubMed ID: 16513620
[TBL] [Abstract][Full Text] [Related]
12. [111In-DOTA]LTT-SS28, a first pansomatostatin radioligand for in vivo targeting of somatostatin receptor-positive tumors.
Maina T; Cescato R; Waser B; Tatsi A; Kaloudi A; Krenning EP; de Jong M; Nock BA; Reubi JC
J Med Chem; 2014 Aug; 57(15):6564-71. PubMed ID: 25007399
[TBL] [Abstract][Full Text] [Related]
13. Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use.
Reubi JC; Schär JC; Waser B; Wenger S; Heppeler A; Schmitt JS; Mäcke HR
Eur J Nucl Med; 2000 Mar; 27(3):273-82. PubMed ID: 10774879
[TBL] [Abstract][Full Text] [Related]
14. Preclinical evaluation of [99mTc/EDDA/tricine/HYNIC0, 1-Nal3, Thr8]-octreotide as a new analogue in the detection of somatostatin-receptor-positive tumors.
Gandomkar M; Najafi R; Shafiei M; Mazidi M; Ebrahimi SE
Nucl Med Biol; 2007 Aug; 34(6):651-7. PubMed ID: 17707805
[TBL] [Abstract][Full Text] [Related]
15. Comparison of 111In-DOTA-NOC and 111I-DOTA-TATE distribution in the target and dose-limiting tissues: conflicting results in vitro and in vivo.
Cihlo J; Melicharová L; Petrik M; Laznickova A; Laznicek M
Anticancer Res; 2008; 28(4B):2189-95. PubMed ID: 18751394
[TBL] [Abstract][Full Text] [Related]
16. Design, synthesis, and biological evaluation of somatostatin-based radiopeptides.
Ginj M; Schmitt JS; Chen J; Waser B; Reubi JC; de Jong M; Schulz S; Maecke HR
Chem Biol; 2006 Oct; 13(10):1081-90. PubMed ID: 17052612
[TBL] [Abstract][Full Text] [Related]
17. New pansomatostatin ligands and their chelated versions: affinity profile, agonist activity, internalization, and tumor targeting.
Ginj M; Zhang H; Eisenwiener KP; Wild D; Schulz S; Rink H; Cescato R; Reubi JC; Maecke HR
Clin Cancer Res; 2008 Apr; 14(7):2019-27. PubMed ID: 18381940
[TBL] [Abstract][Full Text] [Related]
18. Trifunctional somatostatin-based derivatives designed for targeted radiotherapy using auger electron emitters.
Ginj M; Hinni K; Tschumi S; Schulz S; Maecke HR
J Nucl Med; 2005 Dec; 46(12):2097-103. PubMed ID: 16330576
[TBL] [Abstract][Full Text] [Related]
19. DOTA-D-Tyr(1)-octreotate: a somatostatin analogue for labeling with metal and halogen radionuclides for cancer imaging and therapy.
Li WP; Lewis JS; Kim J; Bugaj JE; Johnson MA; Erion JL; Anderson CJ
Bioconjug Chem; 2002; 13(4):721-8. PubMed ID: 12121126
[TBL] [Abstract][Full Text] [Related]
20. A new
Mansi R; Abid K; Nicolas GP; Del Pozzo L; Grouzmann E; Fani M
EJNMMI Res; 2020 Aug; 10(1):90. PubMed ID: 32757150
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
